ImmuPharma plc
IMM.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | £11 | £15 | £5 | £7 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £11 | £14 | £5 | £7 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£0 | £0 | -£0 | £0 |
| % Margin | – | – | – | – |
| EBITDA | -£1 | -£1 | -£1 | -£1 |
| % Margin | – | – | – | – |
| Net Income | -£1 | -£1 | -£1 | -£1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.003 |
| % Growth | 0% | 24% | 0% | – |
| Operating Cash Flow | -£1 | -£1 | -£0 | -£0 |
| Capital Expenditures | £0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£1 | -£1 | -£0 | -£0 |